# US 2004/0082012 A1 · Reversible mhc multimer staining for functional purification of antigen-specific t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082012 A1
- Document ID: US20040082012A1
- Status: Published application
- Kind: A1
- Application number: 10/451,865
- Filed: 2003-12-16
- Published: 2004-04-29
- Earliest claimed: 2000-12-28
- Assignees: Iba GmbH
- Inventors: Dirk H. Busch; Hermann Wagner
- Web page: https://patentgrep.com/patent/US20040082012A1

## CPC

- G01N 33/56972: {White blood cells}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/45: Bacterial antigens
- A61K 40/46: Viral antigens
- C12N 5/0636: {T lymphocytes}
- G01N 33/505: {involving T-cells}
- G01N 33/5094: {for blood cell populations (red blood cells G01N33/80)}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a new method for reversible staining and functional isolation or characterization of cells, e.g. antigen-specific T cells. With this technique, the original functional status of cells can be substantially maintained after their identification and purification. Thus, this new method is of broad benefit for basic research and clinical applications.

## Claims

### Claim 1

A method for reversible staining of cells comprising the steps:
(a) providing a sample comprising a cell having a receptor molecule,
(b) contacting said cell with
(i) at least one component specifically binding to said receptor wherein said at least one component is conjugated to at least one first partner of a binding complex, wherein the component and the receptor exhibit a low-affinity interaction;
(ii) at least one further partner of said binding complex having at least two binding sites for said first partner and
(iii) a detectable label bound to or capable of binding to (i) and/or (ii), wherein the first partner(s) and the further partner(s) of the binding complex are capable of forming a reversible bond and wherein an aggregate comprising at least two components (i), at least one component (ii) and at least one component (iii) is bound via the receptor molecule to said cell, wherein said cell is stained,
(c) optionally separating said stained cell from other components of said sample and
(d) optionally removing said staining from said cell by disrupting the reversible bond.

### Claim 2

A method for reversible staining of T cells comprising the steps:
(a) providing a sample comprising a cell having a T cell receptor (TCR) molecule,
(b) contacting said T cell with
(i) at least one TCR binding ligand comprising a TCR binding peptide and an MHC molecule conjugated to at least one first partner of a binding complex, and
(ii) at least one further partner of a binding complex having at least two binding sites for the first partner of the binding complex and
(iii) a detectable label bound to or capable of binding to (i) and/or (ii), wherein the first partner(s) and the further partner(s) of the binding complex are capable of forming a reversible bond and wherein an aggregate comprising at least two TCR binding ligands (i), at least one component (ii) and at least one component (iii) is bound via the TCR molecule to said T cell, wherein said T cell is stained,
(c) optionally separating said stained T cell from other components of said sample, and
(d) optionally removing said staining from the T cell by disrupting the reversible bond.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2 wherein step (b), step (c) and step (d) are carried out at a temperature of ≦15° C.

### Claim 4 (depends on 3)

The method of claim 3 wherein the temperature is about 4° C.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4 wherein said cell is a mammalian cell.

### Claim 6 (depends on 2, 3, 4, 5)

The method of any one of claims 2-5 wherein said MHC molecule is a soluble mammalian MHC molecule.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6 wherein said staining is removed by contacting said stained cell with a free first partner of said binding complex or an analog of said first partner capable of disrupting the bond between the conjugated first partner (i) and the further partner (ii).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7 wherein the first free partner is a compound which is not detrimental to the cell to be stained.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8 wherein said binding complex is selected from
(a) (i) biotin and (ii) a streptavidin or avidin analog capable of reversible binding of biotin,
(b) (i) a biotin analog capable of reversible binding to streptavidin or avidin and (ii) streptavidin or avidin or a streptavidin or avidin analog capable of reversible binding of said biotin analog, and
(c) (i) a streptavidin or avidin binding peptide and (ii) streptavidin or avidin or a streptavidin or avidin analog capable of reversible binding of said streptavidin or avidin binding peptide.

### Claim 10 (depends on 9)

The method of claim 9 wherein said binding complex is selected from (i) the streptavidin-binding peptide Trp-Ser-His-Pro-Gln-Phe-Glu-Lys and (ii) the streptavidin-analogs streptavidin Val44-Thr45-Ala46-Arg47) and/or streptavidin Ile44-Gly45-Ala46-Arg47.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the binding complex is selected from partners binding in the presence of a divalent cation.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein removal of the staining results in a dissociation of the receptor-binding component from the stained cell.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

Use of the method of any one of claims 1-12 for the isolation of a specific cell population without substantially altering the original functional status thereof.

### Claim 14 (depends on 13)

The use of claim 13 wherein said cell population is an antigen-specific T cell population.

### Claim 15 (depends on 14)

The use of claim 14 for the determination of the functional status of an antigen-specific T cell population.

### Claim 16 (depends on 14)

The use of claim 14 for the purification of an antigen-specific T cell population for in vitro expansion.

### Claim 17 (depends on 14)

The use of claim 14 for the purification of an antigen-specific T cell population for adoptive transfer or immunotherapy.

### Claim 18 (depends on 14)

The use of claim 14 for T cell diagnostics.

### Claim 19

Reagent kit for reversible staining of cells comprising
(i) at least one component specifically binding to a receptor molecule on a cell wherein said at least one component is conjugated to at least one first partner of a binding complex, wherein the component and the receptor exhibit a low-affinity interaction,
(ii) at least one further partner of said complex having at least two binding sites for said first partner, and
(iii) a detectable lable bound or capable of binding to (i) and/or (ii), wherein the first partner(s) and the second partner(s) of the binding complex are capable of forming a reversible bond.

### Claim 20

Reagent kit for reversible staining of T cells comprising
(i) at least one TCR binding ligand comprising at least an MHC molecule conjugated to at least one first partner of a binding complex,
(ii) at least one further partner of a binding complex having at least two binding sites for the first partner of the binding complex and
(iii) a detectable label bound or capable of binding to (i) and/or (ii), wherein the first partner(s) and the further partner(s) of the binding complex are capable of forming a high affinity reversible bond.

### Claim 21 (depends on 20)

The kit of claim 20 wherein the TCR binding ligand further comprises a TCR binding peptide.

### Claim 22 (depends on 20)

The kit of claim 20 wherein a TCR binding peptide having a desired specificity is provided as a separate part.

### Claim 23 (depends on 19, 20, 21, 22)

The kit of any of claims 19-22 further comprising a free first partner of said binding complex or an analog of said first partner capable of disrupting the bond between the conjugated first partner (i) and the further partner (ii).

### Claim 24

Substantially pure target cell population, wherein said cell population is defined by the presence of a specific common receptor and which has been purified from a heterogeneous cell population using an affinity reagent binding to said common receptor, wherein said affinity reagent has been substantially completely removed from said receptor.

### Claim 25

Substantially pure antigen-specific T cell population having a functional status which is substantially unaltered by the purification.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 25)

The cell population of claim 24 or 25 obtainable by the method of any one of claims 1-12.

### Claim 27 (depends on 24, 25, 26)

The cell population of claim 24, 25 or 26 which is free from substantial amounts of TCR binding ligands.

### Claim 28

A fusion polypeptide comprising (a) at least one peptide domain which is a first partner of a binding complex, which is capable of forming a reversible bond with at least one further partner of the binding complex and (b) a ligand domain which binds specifically but with low affinity to a receptor on a cell surface.

### Claim 29

A fusion polypeptide comprising (a) at least one streptavidin-binding peptide and (b) an MHC molecule.
